NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment

Abstract

In chronic lymphocytic leukemia, NOTCH1, SF3B1, BIRC3 and TP53 disruptions are recurrent and affect survival. To define their incidence and clinical impact in patients undergoing first-line treatment, we evaluated 163 cases enrolled in the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) LLC0405 protocol (fludarabine plus alemtuzumab or fludarabine plus cyclophosphamide), for young patients, or in the ML21445 protocol (chlorambucil plus rituximab), for elderly patients. NOTCH1, SF3B1, BIRC3 and TP53 disruptions were detected in 15.9%, 12.2%, 8.6% and 10.4% of cases. NOTCH1 mutations correlated with a shorter treatment-free interval (p = 0.058), an unmutated immunoglobulin heavy variable gene (IGHV) status (p < 0.0001), CD38 and ZAP-70 expression (p = 0.0025 and 0.026, respectively) and trisomy 12 (p = 0.0028), SF3B1 mutations with an unmutated IGHV status (p = 0.02), and BIRC3 disruptions with an unmutated IGHV configuration (p = 0.01) and 11q deletion (p < 0.0001). NOTCH1 and SF3B1 did not appear to impact on overall response, while an inferior response was observed for BIRC3- and TP53-disrupted cases in the LLC0405 and ML21445 protocols, respectively. Progression-free survival, evaluable in the LLC0405 protocol – not affected by NOTCH1, SF3B1 and TP53 – appeared inferior for BIRC3 disruption. NOTCH1 and SF3B1 mutations may be overcome by aggressive regimens, while BIRC3 might impact on outcome also in intensive regimens.

Keywords::

• Chronic lymphocytic leukemia
• novel gene mutations
• first-line treatment

Acknowledgements

This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) Special Program Molecular Clinical Oncology, 5 × 1000, Milan, Italy; Fondo per gli Investimenti della Ricerca di Base (FIRB), Rome, Italy; Compagnia di San Paolo, Turin, Italy; Fondazione Internazionale di Ricerca in Medicina Sperimentale (FIRMS), Torino, Italy; My First AIRC Grant No. 13470, Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy; Futuro in Ricerca, Ministero dell’Istruzione, dell’Università e della Ricerca, Rome, Italy; Progetto Giovani Ricercatori and Ricerca Sanitaria Finalizzata, Ministero della Salute, Rome, Italy; Fondazione Cariplo, Grant No. 2012-0689.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.